Search

A study conducted at Cairo University explored the use of hydroxyapatite nanoparticles (HAP-NPs) in cancer treatment, specifically in Ehrlich solid carcinoma-bearing mice. The research found that HAP-NPs demonstrated significant anticancer activity and when combined with the chemotherapeutic drug Cisplatin, showed even higher efficacy in reducing tumor size. The study concluded that HAP-NPs can induce DNA damage and regulate apoptosis, leading to the selective elimination of tumor cells, with the combined treatment enhancing the activity of Cisplatin within the tumor tissue. [Extracted from the article]

Researchers at Southern Medical University in Guangzhou, China, have developed manganese-based nanozymes that show promise as broad-spectrum antioxidants against cisplatin-induced skeletal muscle atrophy. These nanozymes effectively scavenge reactive oxygen species (ROS) and reduce inflammation, potentially offering a therapeutic approach to combat chemotherapy-associated muscle wasting. The study highlights the potential of nanozyme-based therapeutics not only for muscle atrophy but also for other oxidative stress-related diseases. The research was supported by various funding sources and has been peer-reviewed, offering a novel strategy to address chemotherapy-induced muscle atrophy. [Extracted from the article]

Researchers from Niigata University in Japan have found that an acidic microenvironment can enhance resistance to cisplatin, a key drug used in treating advanced bladder cancer. The study showed that bladder cancer cells cultured in acidic conditions developed resistance to cisplatin, requiring higher concentrations of the drug to achieve toxicity. The research suggests that targeting the acidity of the tumor microenvironment could potentially improve bladder cancer sensitivity to cisplatin. [Extracted from the article]

Researchers at Tanta University have conducted a study on the synergistic anticancer effects of combining cisplatin with an extract from Rumex dentatus L. in treating tongue squamous cell carcinoma. The study utilized various analyses to investigate the potential of this combination treatment, which was found to be more effective in inhibiting proliferation, inducing cell cycle arrest and apoptosis, and reducing autophagy in cancer cells compared to cisplatin alone. The research suggests that this approach could offer a promising new perspective for developing more effective treatments for oral squamous cell carcinoma. [Extracted from the article]

The article discusses a clinical trial, NCT06793215, evaluating the efficacy and safety of divarasib and pembrolizumab compared to pembrolizumab and pemetrexed and carboplatin or cisplatin in treating adult participants with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer. The study aims to assess progression-free survival, overall survival, objective response, and quality of life measures over a period of approximately 5 years. The trial is not yet recruiting participants, with an enrollment target of 600 and a completion date set for February 9, 2030. [Extracted from the article]

A recent study conducted at Shiraz University of Medical Sciences in Iran focused on the effects of Atorvastatin on pro-inflammatory cytokines during cisplatin administration. The double-blind clinical trial involved 30 participants who were divided into two groups, with one group receiving Atorvastatin and the other a placebo. While Atorvastatin showed potential in preventing cisplatin-induced nephrotoxicity, it did not have a significant impact on inflammatory cytokines. The study was approved by the Iranian Registry of Clinical Trial and published in the Journal of Nephropharmacology. [Extracted from the article]

Research from Xijing Hospital of Digestive Diseases has revealed that platinum drugs can increase the expression levels of CXCR4 and PD-L1 in gastric cancer. This study suggests that a combined treatment targeting these molecules may hold promise for gastric cancer patients. The findings indicate that cisplatin-induced upregulation of CXCR4 and PD-L1 is dependent on ROS-dependent pathways, offering potential implications for novel therapeutic approaches in gastric cancer. [Extracted from the article]

A clinical trial, NCT06783140, is being conducted to compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX. The trial involves two arms: one with NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine) and the other with Nab-paclitaxel+gemcitabine. The study aims to assess outcomes such as overall response rate, overall survival time, progression-free survival, duration of response, CA19-9 response, and number of adverse events. The trial is not yet recruiting and is expected to be completed by March 3, 2031. [Extracted from the article]

A clinical trial, NCT06788912, is being conducted to evaluate the effectiveness of Pembrolizumab in combination with other investigational agents in treating resectable non-small cell lung cancer. The trial aims to assess the response to treatment before surgery by measuring the absence of cancer cells in tumors and lymph nodes, as well as the reduction in the number of living cancer cells in the tumor. The study involves various interventions, including neoadjuvant and adjuvant therapies, and has specific outcome measures related to pathological response, adverse events, survival rates, and surgical outcomes. [Extracted from the article]

A study conducted by Nanjing Medical University in Jiangsu, China, explored the role of asprosin in acute kidney injury induced by cisplatin. Asprosin, a peptide involved in metabolism regulation, was found to promote ferroptosis and damage in kidney cells through iron overload and lipid peroxidation. Silencing asprosin was shown to alleviate renal injury and dysfunction in cisplatin-induced acute kidney injury. This research sheds light on potential therapeutic targets for managing acute kidney injury. [Extracted from the article]

Researchers at Hashemite University in Jordan conducted a study on the cardioprotective effects of scopoletin against cisplatin-induced damage in mice. Scopoletin, a natural coumarin, showed potential in reducing oxidative stress, inflammation, and apoptosis caused by cisplatin therapy. The study found that scopoletin effectively mitigated cardiac damage, reduced inflammatory cytokines, and modulated key signaling pathways, suggesting its potential as an adjunctive therapy in cancer treatment. Further clinical investigation is warranted to explore scopoletin's benefits in countering cisplatin's adverse effects. [Extracted from the article]

Researchers at the Universidad Autonoma de Chile conducted a study on gastric cancer, focusing on the use of a combination of Maraviroc and cisplatin to inhibit tumor growth and improve survival rates in mice. The study found that the combination treatment reduced cell viability, inhibited tumor formation, and improved survival rates in mice treated with cisplatin. The researchers concluded that the Maraviroc/cisplatin combination could be a potential complementary therapy for gastric cancer. [Extracted from the article]

Researchers from Lebanese American University conducted a study on the nephroprotective effects of Lebanese Cannabis sativa extract in mice with cisplatin-induced nephrotoxicity. The study found that the cannabis extract prevented apoptosis in podocytes and improved urinary and serum parameters in mice treated with cisplatin. The research suggests that cannabis extract could be a promising approach to protect against cisplatin-induced nephrotoxicity. The study was published in the Journal of Cannabis Research. [Extracted from the article]

A recent study conducted at Harbin Medical University in Heilongjiang, China, explored the association between the overexpression of the gene HYOU1 and cisplatin resistance in patients with cervical cancer. The research identified HYOU1 as significantly upregulated in cervical cancer samples and patients who did not respond to cisplatin treatment. The study suggests that high levels of HYOU1, potentially regulated by EIF3A through m(6)A modifications, could serve as an indicator of cisplatin treatment resistance in cervical cancer patients. This research provides valuable insights into potential mechanisms underlying drug resistance in cervical cancer and highlights the importance of further investigation in this area. [Extracted from the article]

Researchers from the School of Natural Sciences in Sydney, Australia, have developed a new approach for breast cancer therapy by co-loading cisplatin and cyclophosphamide into a nanostructure called UIO-66 and functionalizing it with folic acid. The synthesized nanocarrier showed promising anticancer effects in breast cancer cell lines, reducing cell migration and invasion while enhancing apoptosis. This targeted therapy system demonstrated selective targeting and controlled drug release, potentially increasing the effectiveness of treatment for breast cancer. [Extracted from the article]

Researchers at Huntsman Cancer Hospital conducted a retrospective analysis to evaluate the dosing of gemcitabine and carboplatin in patients with cisplatin-ineligible metastatic urothelial carcinoma. The study found that many patients required dose reductions, delays, and hospitalizations while on this palliative regimen. The research suggests that starting therapy at a reduced dose may help minimize treatment interruptions, dose omissions, and side effects for these patients. This study was funded by Exelixis, Bavarian-Nordic, Clovis, and Bristol-Myers Squibb, and has been peer-reviewed. [Extracted from the article]

The University of Colorado conducted research on acute kidney injury caused by cisplatin, a common chemotherapeutic agent. The study focused on understanding the pharmacokinetics and toxicodynamics of cisplatin-induced kidney injury to predict and prevent it. The research highlighted the importance of incorporating both traditional clinical biomarkers and newer subclinical biomarkers in developing models to predict and prevent cisplatin-induced nephrotoxicity. This study was funded by various NIH institutes and was published in the Journal of Pharmacology and Experimental Therapeutics. [Extracted from the article]

A study conducted at Cangzhou Central Hospital in Hebei, China, explored the role of microsomal glutathione transferase 1 (MGST1) in cisplatin resistance of non-small cell lung cancer (NSCLC) cells. The research found that high MGST1 expression and low arachidonate lipoxygenase 5 (ALOX5) expression were associated with cisplatin resistance in NSCLC patients and cells. The study concluded that targeting MGST1 could potentially overcome cisplatin resistance in NSCLC patients, offering a new therapeutic approach. [Extracted from the article]

Researchers at Fudan University have developed a novel combination therapy involving low-dose cisplatin and a TLR7/8/9 agonist formulation to enhance antitumor immune responses. This therapy showed significant efficacy in abrogating established tumors in mouse models by promoting tertiary lymphatic structure formation and activating immune cells. The study suggests that this combination therapy has the potential to convert 'cold' tumors into 'hot' ones and induce robust antitumor immune responses in vivo. [Extracted from the article]

The article discusses how cisplatin, a common chemotherapy drug, can lead to sensory neurodegeneration and impact the quality of life of patients. The study found that transferring mitochondria from monocytes to damaged sensory neurons can prevent neurotoxicity caused by cisplatin. This process, mediated by connexin 43, shows potential as a therapeutic intervention to alleviate neuropathic pain in cancer patients undergoing chemotherapy. [Extracted from the article]

The article discusses the challenges of cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) and explores the potential of PI3K inhibitors in overcoming this resistance. The study found that PI3K inhibitors can effectively bypass Nrf2-mediated cisplatin resistance in HNSCC by inducing metabolic changes and re-sensitizing resistant cells to cisplatin. The research highlights the therapeutic potential of PI3K inhibitors, specifically gedatolisib, in combination therapies to address primary chemo-radiation failure in HNSCC. [Extracted from the article]

Researchers from Heilongjiang Bayi Agricultural University in Daqing, China, conducted a study on the protective effects of Epigallocatechin gallate (EGCG) on intestinal injury induced by Cisplatin (CIS) in rats. The study found that EGCG alleviated CIS-induced intestinal damage, with the 40 mg/kg dose showing the most significant protective effect. EGCG treatment influenced the gut microbiota, metabolic pathways, and inhibited proteins associated with autophagy and the NRF2/Keap1 signaling pathway. The research concluded that EGCG ameliorates CIS-induced hepatoenteric toxicity by regulating intestinal flora and targeting the Nrf2/Keap1 signal axis. [Extracted from the article]

Researchers at Jilin Agricultural University in China have discovered that chiisanoside derivatives from Acanthopanax sessiliflorus can activate autophagy through the LRP6/GSK3b axis, inhibiting oxidative stress and potentially counteracting cisplatin-induced ototoxicity. Compound 19, a derivative of chiisanoside, showed significant protective activity against cisplatin-induced ototoxicity in cell and mouse models. The study suggests that compound 19 could prevent ototoxicity by activating autophagy, offering a new approach to treating cisplatin-induced ototoxicity and sensorineural hearing loss. [Extracted from the article]

Researchers from the Second Hospital of Lanzhou University have identified that overactivation of SRC is associated with cisplatin resistance in bladder cancer. SRC activates pathways that increase nucleotide synthesis and NADPH production, protecting cancer cells from cisplatin-induced DNA damage. Targeting SRC with inhibitors like eCF506 shows promise in overcoming cisplatin resistance and enhancing sensitivity to treatment. This study provides new insights for combination therapy in bladder cancer. [Extracted from the article]

Researchers at CHA Bundang Medical Center in South Korea conducted a study on the effects of cisplatin therapy on renal injury in mice. They administered cisplatin and lipopolysaccharide to mice and observed significant renal damage, including tubular damage and fibrosis. The study concluded that co-administration of cisplatin and LPS resulted in a distinct renal injury model in mice. This research provides valuable insights into the potential nephrotoxic side effects of cisplatin therapy. [Extracted from the article]

A study conducted at Nagoya City University focused on predicting cisplatin-induced acute kidney injury (Cis-AKI) using an interpretable machine learning model and electronic medical record information. The research included 1253 hospitalized patients who received cisplatin chemotherapy, with 9.5% developing Cis-AKI. The study found that the concomitant use of intravenous magnesium preparations was negatively correlated with Cis-AKI, suggesting the potential benefits of magnesium in preventing AKI. The model developed in the study showed promise in predicting Cis-AKI early, potentially aiding in its avoidance. [Extracted from the article]

A recent study conducted at Tianjin Medical University in the People's Republic of China explored the role of Proteinase-activated receptor-2 (PAR2) in lung adenocarcinoma (LUAD). The research found that high levels of PAR2 were associated with poor differentiation, lymphatic invasion, and reduced survival rates in LUAD patients. Additionally, PAR2 inhibition increased apoptosis in lung cancer cells induced by cisplatin therapy. This peer-reviewed study sheds light on the potential impact of PAR2 on malignancy in lung adenocarcinoma. [Extracted from the article]

Researchers have submitted a patent application for a method to alleviate resistance to chemotherapy in patients with solid tumors, including lung cancer. The method involves administering a composition that targets the interaction between integrin b4 and paxillin, potentially overcoming resistance to platinum-based chemotherapy drugs like cisplatin. This innovation aims to expand therapeutic options for patients facing chemoresistance, offering a promising approach to improve cancer treatment outcomes. [Extracted from the article]

Researchers at Baqiyatallah University of Medical Sciences in Tehran, Iran, have identified a novel mechanism of cisplatin resistance in ovarian cancer involving the long non-coding RNA LINC02381. The study reveals that interleukin-12 (IL-12) induces Wnt signaling, leading to increased expression of LINC02381, which in turn upregulates ATP-binding cassette (ABC) transporters, reducing cisplatin concentration in cancer cells. Targeting this IL-12/Wnt/TCF7/LINC02381 axis may offer promising therapeutic strategies to overcome chemotherapy resistance in ovarian cancer. Further research is needed to validate these mechanisms and explore potential interventions to disrupt this feedback loop. [Extracted from the article]

A recent study conducted at Asan Medical Center in Korea examined the efficacy and toxicity of paclitaxel-cisplatin-bevacizumab as a first-line treatment for platinum-naive primary stage IVB cervical cancer. The study included 61 patients with a median age of 56 years, who received a median of 9 cycles of treatment. The research found that a reduction rate of 40% in cervical mass size during treatment could be a potential prognostic factor for progression-free survival in these patients. The study concluded that paclitaxel-cisplatin-bevacizumab is effective and well-tolerated for this type of cancer. [Extracted from the article]

Researchers from Charite University Hospital and School of Medicine have found that high Ano1 expression is a key driver of resistance to radiation and cisplatin in HPV-negative head and neck squamous cell carcinoma. The study analyzed the impact of Cyclin D1 and Ano1 overexpression on survival and identified potential treatment combinations for high-risk patient groups. The findings suggest that Copanlisib and afatinib could be promising candidates for combination therapy in 11q13-amplified HNSCC tumors. [Extracted from the article]

A study conducted at the Cancer Institute Hospital in Tokyo, Japan, explored the relevance of lymph-node ratio (LNR) as a risk factor for recurrence in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy. The research found that a higher LNR was associated with worse disease-free survival rates and increased recurrence following treatment with docetaxel, cisplatin, and 5-fluorouracil. This study provides valuable insights into the clinical utility of LNR in predicting outcomes for patients with ESCC. [Extracted from the article]

A randomized phase II trial, NCT06770582, compares pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C and radiation therapy for non-muscle invasive bladder cancer treatment. The trial aims to evaluate bladder-intact event-free survival, complete response by cystoscopy, disease-free survival, local-regional control, metastasis-free survival, overall survival, and quality of life. Patients will be followed up for up to 5 years to assess outcomes and adverse events. The trial is not yet recruiting and aims to enroll 160 participants by February 1, 2032. [Extracted from the article]

The article discusses the potential protective effects of 4-methylpyrazole (4MP) in preventing cisplatin-induced nephrotoxicity (CIN) in bladder cancer patients. The study found that 4MP inhibited the activity of cytochrome P450 2E1 (CYP2E1) in the kidneys, reducing cell death in male mice and human kidney cells without interfering with cisplatin's anti-cancer effects in bladder cancer cells. The research suggests that inhibiting CYP2E1 with 4MP could be a prophylactic therapeutic option to prevent CIN in bladder cancer patients. [Extracted from the article]

A study conducted at Nantong University in Jiangsu, China, focused on investigating the role of NT5E in cisplatin resistance in non-small cell lung cancer (NSCLC). The research found that NT5E regulates drug resistance in NSCLC cells through the PI3K-AKT signaling pathway and is associated with poor prognosis in patients. The study provides insights into the mechanisms of drug resistance in lung cancer and may lead to the development of new therapeutic strategies. [Extracted from the article]

A recent study conducted at Shiraz University in Iran focused on the aggregation of Cisplatin in aqueous solutions, a widely used metallodrug for cancer treatment. The research utilized molecular dynamics simulations to investigate the impact of Cisplatin on water structure at various concentrations. The study found that Cisplatin molecules begin to self-aggregate at 0.5 molal concentration, leading to changes in solution structures and volumes. The research, which has been peer-reviewed, provides valuable insights into the behavior of Cisplatin in aqueous environments. [Extracted from the article]

Researchers have submitted a patent application for "Compositions and Methods for the Prevention and Treatment of Hearing Loss" to the USPTO. The application focuses on administering inhibitors of epidermal growth factor receptor signaling to prevent hearing loss. The patent application details methods to prevent ototoxicity and cisplatin-induced hearing loss through the use of specific inhibitors. The research aims to address hearing disorders and conditions through pharmaceutical compositions. [Extracted from the article]

The article discusses the role of the SLC6A6 taurine transporter in protecting ovarian cancer precursor cells with mutant p53R175H from cisplatin treatment. Mutant p53 protein expression in these cells was found to induce resistance to cisplatin, and targeting the SLC6A6 transcript resensitized the cells to treatment. The study suggests that loss of SLC6A6 alters mechanisms involved in cell survival in response to DNA damage, providing insights into the evolution of ovarian cancer. [Extracted from the article]